Hypophosphatemia News and Research

RSS
New drug could alleviate symptoms of rare musculoskeletal condition

New drug could alleviate symptoms of rare musculoskeletal condition

Inherited form of rickets improves more with new injectable medicine than conventional therapy

Inherited form of rickets improves more with new injectable medicine than conventional therapy

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

FDA approves new treatment for people with hairy cell leukemia

FDA approves new treatment for people with hairy cell leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

Osteopontin plays a role in X-linked hypophosphatemia

Osteopontin plays a role in X-linked hypophosphatemia

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of perifosine and temsirolimus shows promise against malignant glioma

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC